718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cance...

by Cong Li, Gregory Moore, Umesh Muchhal, John Desjarlais, Matthew Bernett, Madeline Fort, Lingming Liang, Tao Osgood, Rodolfo Yabut, Sarav Kaliyaperumal, John Harrold, Jude Canon, Anna Rogojina, Raushan Kurmasheva, Peter Houghton, Olivier Nolan-Stevaux
Published 2020-11-01